Literature DB >> 3568423

Serum pepsinogens I and II and stomach cancer.

G N Stemmermann, I M Samloff, A M Nomura, L K Heilbrun.   

Abstract

Prospective epidemiologic studies among Hawaiian Japanese men have shown that a serum pepsinogen I (PG I) level below 20 ng/ml is highly specific for extensive intestinal metaplasia of the stomach and for the intestinal type of stomach cancer. The test, however, shows a low level of sensitivity as a predictor of the intestinal type stomach cancer. Since antralization of the corpus, as encountered in Type A atrophic gastritis and late stage Type B gastritis, results in an increase of PG II relative to PG I, we examined the sensitivity and specificity of the PG I/PG II ratio as a predictor of gastric cancer. Using a cut-off point of 2.0 in the ratio to separate subjects at high and low risk for stomach cancer, we found a modest improvement in the level of sensitivity with a small decrease in specificity. Abnormally low PG I levels and PG I/PG II ratios were associated mainly with advanced stages of the intestinal type of cancer and therefore, are not useful screening tests to identify early cases of gastric cancer. The use of the PG I/PG II ratio resulted in a modest improvement in the level of sensitivity with a small decrease in specificity.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3568423     DOI: 10.1016/0009-8981(87)90022-2

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  17 in total

1.  Accuracy of screening for gastric cancer using serum pepsinogen concentrations.

Authors:  F Kitahara; K Kobayashi; T Sato; Y Kojima; T Araki; M A Fujino
Journal:  Gut       Date:  1999-05       Impact factor: 23.059

2.  Gastric cancer screening using the serum pepsinogen test method.

Authors:  Kazumasa Miki
Journal:  Gastric Cancer       Date:  2006-11-24       Impact factor: 7.370

3.  Inverse relation of serum Helicobacter pylori antibody titres and extent of intestinal metaplasia.

Authors:  H Osawa; F Inoue; Y Yoshida
Journal:  J Clin Pathol       Date:  1996-02       Impact factor: 3.411

4.  Validation of the pepsinogen test method for gastric cancer screening using a follow-up study.

Authors:  Shigeto Mizuno; Masao Kobayashi; Shohken Tomita; Ikuya Miki; Atsuhiro Masuda; Mitsuko Onoyama; Yasuki Habu; Hideto Inokuchi; Yoshiyuki Watanabe
Journal:  Gastric Cancer       Date:  2009-11-05       Impact factor: 7.370

5.  The relationship between serum ghrelin and the risk of gastric and esophagogastric junctional adenocarcinomas.

Authors:  Gwen Murphy; Farin Kamangar; Sanford M Dawsey; Frank Z Stanczyk; Stephanie J Weinstein; Philip R Taylor; Jarmo Virtamo; Christian C Abnet; Demetrius Albanes; Neal D Freedman
Journal:  J Natl Cancer Inst       Date:  2011-06-21       Impact factor: 13.506

6.  Statistical analysis of serum pepsinogen I (PG I) and II (PG II) levels, PG I/PG II ratios and serum gastrin levels in a general population.

Authors:  A Kazuo; M Junichi
Journal:  Environ Health Prev Med       Date:  1996-10       Impact factor: 3.674

7.  Serum pepsinogen in screening for gastric cancer.

Authors:  A Kodoi; M Yoshihara; K Sumii; K Haruma; G Kajiyama
Journal:  J Gastroenterol       Date:  1995-08       Impact factor: 7.527

8.  Serum pepsinogens and risk of gastric and oesophageal cancers in the General Population Nutrition Intervention Trial cohort.

Authors:  J-S Ren; F Kamangar; Y-L Qiao; P R Taylor; H Liang; S M Dawsey; B Liu; J-H Fan; C C Abnet
Journal:  Gut       Date:  2009-01-09       Impact factor: 23.059

9.  Serum pepsinogens and risk of esophageal squamous dysplasia.

Authors:  Farin Kamangar; Lena Diaw; Wen-Qiang Wei; Christian C Abnet; Guo-Qing Wang; Mark J Roth; Bing Liu; Ning Lu; Carol Giffen; You-Lin Qiao; Sanford M Dawsey
Journal:  Int J Cancer       Date:  2009-01-15       Impact factor: 7.396

10.  Association between upper digestive tract microbiota and cancer-predisposing states in the esophagus and stomach.

Authors:  Guoqin Yu; Mitchell H Gail; Jianxin Shi; Vanja Klepac-Ceraj; Bruce J Paster; Bruce A Dye; Guo-Qing Wang; Wen-Qiang Wei; Jin-Hu Fan; You-Lin Qiao; Sanford M Dawsey; Neal D Freedman; Christian C Abnet
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-04-03       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.